NCT05525039 RCT of Combination Effect of Vibration Treatment and HMB Supplementation on Myosteatosis and NMJ Degeneration
| NCT ID | NCT05525039 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Chinese University of Hong Kong |
| Condition | Sarcopenia |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2023-01-12 |
| Primary Completion | 2025-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 200 participants in total. It began in 2023-01-12 with a primary completion date of 2025-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The investigators' pre-clinical study confirms the positive effects of combined treatment (VT + HMB) on reducing fat-to-lean tissue ratio, intramuscular fat infiltration and increasing muscle strength in sarcopenia animal model. The results showed that fat mass could be decreased by \~32%, while histology Oil Red O staining indicated a decrease of fat by almost 60%; in contrast, lean muscle mass increased by \~14%. On muscle strength, combined treatment increased twitch force, tetanic force and grip strength by \~30-66%. These in vivo results are very encouraging and the investigators should explore its potential in clinical translation. As VT and HMB supplement have been commercially available and their compliance rates are satisfactory, they can be translated to clinical application easily. The investigators' next step is to confirm its clinical efficacy, so that sarcopenia becomes a new indication of VT and HMB. The hypothesis is that combined treatment of VT and HMB can retard the progression of sarcopenia in human, in terms of muscle mass, muscle strength and performance.
Eligibility Criteria
Inclusion Criteria: * Subjects aged 60 years or above * Subjects failed in AWGS algorithm 1. skeletal muscle mass by BIA (male at \<7.0 kg/m\^2, female at \<5.7 kg/m\^2), and 2. handgrip strength (male at \<28 kg, female at \<18kg), and/or 3. gait speed test (\>1m/s) Exclusion Criteria: * Subjects with pathological bone diseases * Subjects with chronic inflammatory condition (e.g. rheumatoid arthritis) * Subjects with neurological problems * Subjects receiving regular exercise * Subjecs who are chair-/bed- bound * Subjects with malignancy * Subjects with cardiovascular concern such as with pace-maker in-situ * Subjects with acute fractures or severe osteoarthritis
Contact & Investigator
Wing Hoi Cheung, PhD
PRINCIPAL INVESTIGATOR
Chinese University of Hong Kong
Frequently Asked Questions
Who can join the NCT05525039 clinical trial?
This trial is open to participants of all sexes, aged 60 Years or older, studying Sarcopenia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05525039 currently recruiting?
Yes, NCT05525039 is actively recruiting participants. Contact the research team at louischeung@cuhk.edu.hk for enrollment information.
Where is the NCT05525039 trial being conducted?
This trial is being conducted at Hong Kong, Hong Kong, Hong Kong, Hong Kong, Hong Kong, Hong Kong.
Who is sponsoring the NCT05525039 clinical trial?
NCT05525039 is sponsored by Chinese University of Hong Kong. The principal investigator is Wing Hoi Cheung, PhD at Chinese University of Hong Kong. The trial plans to enroll 200 participants.